ORIGINAL PAPER
Neonatal cholestasis in Jordanian children: a single-center experience
1
Pediatric Department, Faculty of Medicine, Jordan University of Science and Technology, Ar-Ramtha, Jordan
2
Pediatric Department, Cleveland Clinic, Ohio, United States
3
King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia
Submission date: 2023-06-11
Final revision date: 2023-08-24
Acceptance date: 2023-08-26
Publication date: 2023-12-15
Pediatr Pol 2023;98(4):300-306
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Neonatal cholestasis refers to conjugated hyperbilirubinemia that either presents at birth or develops within the first three months of life. The causes of neonatal cholestasis are extensive and can be classified based on the anatomical location of the pathology into extrahepatic and intrahepatic causes This study aimed to assess the frequency and underlying etiologies of neonatal cholestasis in a tertiary care center in Jordan.
Material and methods:
We retrospectively reviewed the medical records of infants diagnosed with neonatal cholestasis during the study period. Demographic data, clinical presentations, laboratory results, imaging studies, and liver biopsies were collected and analyzed. Data were presented as percentages and averages.
Results:
Of the 47 patients diagnosed with neonatal cholestasis, 55.3% were male, and the average age at presentation was 16.7 days. Jaundice was the most common clinical feature (100%), followed by clay-colored stools and dark urine (29.7%). Notably, 12.8% of patients had skeletal abnormalities. At presentation, the average total and direct bilirubin levels were 14.3 mg/dl (± SD 7.3 mg/dl) and 10.1 mg/dl (± SD 6.5 mg/dl), respectively. Abnormal liver ultrasound findings were observed in 8 patients (17%). In our cohort, metabolic and genetic disorders were the most common underlying causes of neonatal cholestasis, followed by extrahepatic anatomical biliary disorders.
Conclusions:
Causes of neonatal cholestasis vary depending on the population. Metabolic and genetic disorders were the leading causes of death in our cohort. Hence, genetic testing may help reduce costs and fruitless investigations in affected infants.
Neonatal cholestasis refers to conjugated hyperbilirubinemia that either presents at birth or develops within the first three months of life. The causes of neonatal cholestasis are extensive and can be classified based on the anatomical location of the pathology into extrahepatic and intrahepatic causes This study aimed to assess the frequency and underlying etiologies of neonatal cholestasis in a tertiary care center in Jordan.
Material and methods:
We retrospectively reviewed the medical records of infants diagnosed with neonatal cholestasis during the study period. Demographic data, clinical presentations, laboratory results, imaging studies, and liver biopsies were collected and analyzed. Data were presented as percentages and averages.
Results:
Of the 47 patients diagnosed with neonatal cholestasis, 55.3% were male, and the average age at presentation was 16.7 days. Jaundice was the most common clinical feature (100%), followed by clay-colored stools and dark urine (29.7%). Notably, 12.8% of patients had skeletal abnormalities. At presentation, the average total and direct bilirubin levels were 14.3 mg/dl (± SD 7.3 mg/dl) and 10.1 mg/dl (± SD 6.5 mg/dl), respectively. Abnormal liver ultrasound findings were observed in 8 patients (17%). In our cohort, metabolic and genetic disorders were the most common underlying causes of neonatal cholestasis, followed by extrahepatic anatomical biliary disorders.
Conclusions:
Causes of neonatal cholestasis vary depending on the population. Metabolic and genetic disorders were the leading causes of death in our cohort. Hence, genetic testing may help reduce costs and fruitless investigations in affected infants.
REFERENCES (36)
1.
Feldman A, Suchy FJ. Approach to the infant with cholestasis. In: Liver Disease in Children. Feldman A, Suchy FJ, Balistreri WF (eds.). 1st ed. Cambridge University Press, Cambridge 2014; 101-110.
3.
Pandita A, Gupta V, Gupta G. Neonatal cholestasis: a Pandora’s box. Clin Med Insights Pediatr 2018; 12: 1179556518805412.
4.
Fawaz R, Baumann U, Ekong U, et al. Guideline for the evaluation of cholestatic jaundice in infants: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr 2017; 64: 154-168.
7.
Balistreri WF, Bezerra JA. Whatever happened to “neonatal hepatitis”? Clin Liver Dis 2006; 10: 27-53.
9.
Dehghani SM, Efazati N, Shahramian I, et al. Evaluation of chole- stasis in Iranian infants less than three months of age. Gastroenterol Hepatol Bed Bench 2015; 8: 42-48.
10.
Shahraki T, Miri-Aliabad G, Shahraki M. Frequency of different causes of infant cholestasis in a tertiary referral center in South-East Iran. Iran J Pediatr 2018; 28: e65409.
11.
Abdullah AM, al Fadel Saleh M, al Madan M, et al. Infantile cholestasis in the Central-Eastern Province Saudi Arabia. J Trop Pediatr 1997; 43: 138-142.
12.
Suchy FJ. Approach to the infant with cholestasis. In: Liver Disease in Children. Suchy FJ, Sokol RJ, Balistreri WF (eds.). 3rd ed. Cambridge University Press, Cambridge 2007.
13.
De Bruyne R, Van Biervliet S, Vande Velde S, et al. Clinical practice: neonatal cholestasis. Eur J Pediatr 2011; 170: 279-284.
14.
Fischler B, Papadogiannakis N, Nemeth A. Aetiological factors in neonatal cholestasis. Acta Paediatrica 2001; 90: 88-92.
15.
Lee WS, Chai PF, Boey CM, et al. Aetiology and outcome of neonatal cholestasis in Malaysia. Singapore Med J 2010; 51: 434-439.
16.
Yerushalmi B, Sokol RJ, Narkewicz MR, et al. Niemann-pick disease type C in neonatal cholestasis at a North American Center. J Pediatr Gastroenterol Nutr 2002; 35: 44-50.
17.
Sharma D, Sharma P, Agrawal R. Neonatal cholestasis syndrome: morbidities and outcomes in a tertiary care center in India. Indian J Pediatr 2016; 83: 1449-1455.
18.
Al-Refaee F, Al-Manea H. A review of the etiology and clinical presentation of neonatal cholestasis: a single-center experience. J Clin Neonatol 2014; 3: 192-196.
19.
Kalyoncu D, Ünal F, Akçam M, et al. Evaluation of infants with neonatal cholestasis: experience of a tertiary referral center in Turkey. J Trop Pediatr 2019; 65: 276-283.
20.
Al-Sayed M, Rashed M, Al-Rashed M. Infantile cholestasis in the Central-Eastern Province Saudi Arabia. Saudi J Gastroenterol 2003; 9: 119-123.
21.
Khalesi M, Rezaei M, Farahmand F. Evaluation of cholestatic jaundice in infants. Iran J Pediatr 2006; 16: 289-294.
22.
American Academy of Pediatrics Subcommittee on Hyperbilirubinemia. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics 2004; 114: 297-316.
23.
Gunaydin M, Bozkurter Cil AT. Progressive familial intrahepatic cholestasis: diagnosis, management, and treatment. Hepat Med 2018; 10: 95-104.
24.
Balistreri WF. Inherited disorders of bile acid transport or synthesis. Gastroenterol Hepatol (NY) 2007; 3: 343-345.
25.
Al-Qudah RA, Alkaiyat MK, Alomari H, et al. Mothers’ knowledge and attitudes about newborn screening in Jordan. J Pediatr Nurs 2020; 52: e48-e52.
26.
Prasad R, Kapoor K, Gupta RK. Prevalence and outcome of hepatobiliary dysfunction in neonatal septicaemia. J Clin Diagn Res 2017; 11: SC08-SC10.
27.
Rubio-Gozalbo ME, Gubbels CS, Bakker JA, et al. Sweet and sour: an update on classic galactosemia. J Inherit Metab Dis 2009; 32: 730-742.
28.
Ceylaner S, Ceylaner G, Temiz A, et al. Usefulness of magnetic resonance cholangiopancreatography in pancreatobiliary abnormalities in pediatric patients. J Pediatr Surg 2014; 49: 113-117.
29.
Lopes MF Jr., Nogueira Neto JF, de Morais MB. Endoscopic retrograde cholangiopancreatography in infants and children. J Pediatr (Rio J) 2003; 79: 301-306.
30.
Maqbool S, Hasan A, Saeed A, et al. Conjugated hyperbilirubinemia in infants: is there still a role for ERCP? J Coll Physicians Surg Pak 2011; 21: 280-282.
31.
Cui J, Tinney FJ, Augustine MV, et al. Relationship between stool color and excretion on two-day stool collection in neonates. Pediatrics 2017; 140 (1 Meeting abstract): 56.
32.
Peluso A, Patrinos ME. Clinical outcomes of liver transplantation in pediatric patients with mitochondrial disorders: a single-center experience. Pediatrics 2018; 142 (1 Meeting abstract): 214.
33.
Robie DK, Overfelt SR, Xie L. Differentiating biliary atresia from other causes of cholestatic jaundice. Am Surg 2014; 80: 827-831.
34.
Azar G, Beneck D, Lane B, et al. Atypical morphologic presentation of biliary atresia and value of serial liver biopsies. J Pediatr Gastroenterol Nutr 2002; 34: 212-215.
35.
Petersen C. Pathogenesis and treatment opportunities for biliary atresia. Clin Liver Dis 2006; 10: 73-88.
36.
Cui J, Tinney FJ, Augustine MV, et al. Relationship between stool color and excretion on day of life 5 and subsequent diagnosis of biliary atresia. Pediatrics 2017; 140 (1 Meeting abstract): e20170156.
Share
RELATED ARTICLE
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
